AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06360042
Drug: Camrelizumab plus Apatinib
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: camrelizumab 200mg intravenously every 2 weeks plus Apatinib 250mg orally once daily
Trial: NCT04628572
Drug: Ceftazidime-avibactam
RxNorm normalized name: avibactam
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-Interventional Study
Trial: NCT06283134
Drug: toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BioTTT001 in combination with toripalimab and regorafenib period: toripalimab 80mg intravenous D1 and D15, 4 weeks per cycle.
Trial: NCT06283134
Drug: regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BioTTT001 in combination with toripalimab and regorafenib period: regorafenib 80 mg oral administration, D1-D21, 4 weeks per cycle.
Trial: NCT05246371
Drug: Propofol, dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive maintenance of general anesthesia by TIVA using combination of propofol and dexmedetomidine.
Trial: NCT05246371
Drug: Desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive maintenance of general anesthesia by desflurane.
Trial: NCT06367517
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab administrated at a dose of 8 mg/kg, given once every four weeks
Trial: NCT06310616
Drug: Loestrin
RxNorm normalized name: Lo Loestrin Fe
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loestrin will be administered.
Trial: NCT04699383
Drug: Sodium Stibogluconate with allopurinol
RxNorm normalized name: sodium stibogluconate
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine administration of SSG/allopurinol combination treatment, from 1-5 cycles
Trial: NCT05193604
Drug: Anlotinib Hydrochloride Capsule
RxNorm normalized name: loperamide hydrochloride Oral Capsule
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
Trial: NCT05193604
Drug: Gemcitabine hydrochloride for injection
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy medicine for metastatic pancreatic cancer
Trial: NCT05193604
Drug: Paclitaxel for injection (albumin bound)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy medicine for metastatic pancreatic cancer
Trial: NCT04970654
Drug: somapacitan
RxNorm normalized name: Somapacitan
DrugBank: Somapacitan (DB15093)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Somapacitan (0.16 mg/kg/week) will be administered subcutaneously (s.c.; under the skin) once weekly by PDS290 pen-injector. Somapacitan can be injected any time during the once weekly dosing day. The dose will be calculated based on the subject's current body weight.
Trial: NCT05302804
Drug: Menthol Gel
RxNorm normalized name: MENTHOL GEL,TOP
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% menthol gel applied from shoulder to wrist and mid thigh to ankle, 30 minute treadmill walk (3.5 mph at 5% grade at 38°C, 60% relative humidity)
Trial: NCT05302804
Drug: Control Gel
RxNorm normalized name: SALICYLIC ACID 20 mg in 1 mL TOPICAL GEL [Walgreens Acne Control Gel]
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypoallergenic gel applied from shoulder to wrist and mid thigh to ankle, 30 minute treadmill walk (3.5 mph at 5% grade at 38°C, 60% relative humidity)
Trial: NCT06134388
Drug: Sulfasalazine
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfasalazine is an anti-inflammatory drug that is indicated for treatment of ulcerative colitis and rheumatoid arthritis.
Trial: NCT04246762
Drug: Olokizumab
RxNorm normalized name: olokizumab
DrugBank: Olokizumab (DB13127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile solution for subcutaneous (SC) injection, 128 mg (0.8 mL injection)
Trial: NCT04246762
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, 20 mg, oral
Trial: NCT04246762
Drug: Warfarin+ Vitamin K
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin -Tablets 10 mg (containing 5 mg S-warfarin), oral. Vitamin K - solution for intravenous injection, 10 mg/mL ampoule, orally.
Trial: NCT04246762
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Syrup, 2 mg/mL, oral
Trial: NCT04643405
Drug: APG-1387 for Injection
RxNorm normalized name: APGA
DrugBank: APG-1387 (DB16095)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APG1387 will be administered IV days 1， 8, 15 and 22 of a 28 day cycle.
Trial: NCT04643405
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000 mg/m\^2 will be administered IV days 1, 8, and 15 of a 28 day cycle.
Trial: NCT04643405
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-Paclitaxel 125mg/m\^2 will be administered IV days 1, 8, and 15 of a 28 day cycle.
Trial: NCT00002092
Drug: Cimetidine
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05826951
Drug: Alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol (0.8g/kg)
Trial: NCT03692312
Drug: Tideglusib
RxNorm normalized name: Tideglusib
DrugBank: Tideglusib (DB12129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tideglusib for oral suspension, weight-adjusted at 400mg, 600mg or 1000 mg dose levels, once daily
Trial: NCT04713670
Drug: (A) T-V14
RxNorm normalized name: (T,G)-A-L
DrugBank: Glatiramer (DB05259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vonoprazan(vocinti)-based triple therapy for 14 days (T-V14)
Trial: NCT04713670
Drug: (B) T-V7
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vonoprazan(vocinti)-based triple therapy for 7 days (T-V7)
Trial: NCT04713670
Drug: (C) D-V14
RxNorm normalized name: D
DrugBank: Rosomidnar (DB17154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vonoprazan(vocinti)-based dual therapy for 14 days (D-V14)
Trial: NCT04713670
Drug: (D) HD-V14
RxNorm normalized name: D
DrugBank: Rosomidnar (DB17154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vonoprazan(vocinti)-based high dose dual therapy for 14 days (HD-V14)
Trial: NCT04713670
Drug: (F) RH-V14
RxNorm normalized name: RH-OLIGOPEPTIDE-2
DrugBank: Mecasermin (DB01277)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: vonoprazan(vocinti)-based reverse hybrid therapy for 14 days (RH-V14)
Trial: NCT04713670
Drug: (H) T-L14
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole(takepron)-based triple therapy for 14 days (T-L14)
Trial: NCT05315024
Drug: Imiquimod cream
RxNorm normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imiquimod cream
Trial: NCT04964479
Drug: Anlotinib Hydrochloride Capsules
RxNorm normalized name: loperamide hydrochloride Oral Capsule
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12mg capsule once daily
Trial: NCT04964479
Drug: Pembrolizumab injection
RxNorm normalized name: pembrolizumab Injection
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg injection once every 3 week
Trial: NCT06164665
Drug: Pioglitazone 15mg
RxNorm normalized name: METFORMIN 500MG/PIOGLITAZONE 15MG TAB
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone (PIO) will be administered as a 15 mg oral dose per day for 5 days
Trial: NCT06513234
Drug: Orelabrutinib and obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Rutin (DB01698)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Orelabrutinib and obinutuzumab 6cycles ;orelabrutinib 150mg
Trial: NCT06231277
Drug: BH002
RxNorm normalized name: Buprenorphine Hydrochloride
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Every 21 days constitutes a treatment cycle, and administration begins on the first day of each cycle
Trial: NCT05295875
Drug: ALT-801
RxNorm normalized name: ALT-801
DrugBank: ALT-801 (DB15386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected subcutaneously (SC)
Trial: NCT05663580
Drug: Cabotegravir 600mg/3mL, Rilpivirine 900mg/3mL
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Initial administration of two separate intramuscolar injection of cabotegravir 400mg/3mL and rilpivirine 600mg/3mL in opposite gluteal muscles, repeated one month later and then every two months.
Trial: NCT05677282
Drug: Rifaximin 550 MG
RxNorm normalized name: rifAXIMin 550 MG
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin 550 mg as a single dose administered orally.
Trial: NCT05677282
Drug: Loperamide
RxNorm normalized name: Loperamide
DrugBank: Loperamide (DB00836)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg loperamide administered orally with study antibiotic (rifaximin or azithromycin). Additional loperamide to use as needed, but not to exceed 16 mg/day for 2 days as per licensed use (one 2 mg capsule after each looses stool).
Trial: NCT03137966
Drug: Deferoxamine
RxNorm normalized name: Deferoxamine
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deferoxamine (0.66mg/ml) will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
Trial: NCT04536077
Drug: CDX-301
RxNorm normalized name: CDX-301
DrugBank: CDX-301 (DB19293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug will be supplied free of charge by Celldex
Trial: NCT04536077
Drug: CDX-1140
RxNorm normalized name: CDX
DrugBank: Cefadroxil (DB01140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The drug will be supplied free of charge by Celldex
Trial: NCT05505539
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intralesionally by injection
Trial: NCT03806751
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.
Trial: NCT05019729
Drug: VRC-MALMAB0114-00-AB
RxNorm normalized name: AB-8939
DrugBank: AB-8939 (DB17115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC-MALMAB0114-00-AB (L9LS) is a monoclonal antibody that binds an epitope of the Plasmodium falciparum circumsporozoite protein.
Trial: NCT05659927
Drug: MG-ZG122 Humanized Monoclonal Antibody Injection
RxNorm normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.
Trial: NCT06555146
Drug: Semaglutide, 0.5 mg/mL
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 subcutaneous injection on baseline day
Trial: NCT05205291
Drug: Lipopolysaccharide
RxNorm normalized name: Lipopolysaccharide
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive one dose of Lipopolysaccharide (1ng/Kg) after the first PET/MR scan with \[11C\]PBR28 and four hours before the second PET/MR scan with \[11C\]PBR28.
Trial: NCT00003858
Drug: mitoxantrone hydrochloride
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06556199
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Selinexor dose escalation: 40,60,80mg respectively every week, and dose expansion at the RP2D of Selinexor,every 3 weeks for 6 cycles.
Trial: NCT06556199
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide 150mg/m2 po d1-5 every 3 weeks for 6 cycles.
Trial: NCT06556199
Drug: Anti-PD-1 monoclonal antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of anti-PD-1 monoclonal antibody is fixed dose 200 mg intravenously every 3 weeks until until disease progression or recurrence, intolerance of toxicity, death, loss of follow-up, withdrawal of notification (whatever happened first).
Trial: NCT05532358
Drug: Fluvoxamine 100 mg QD for 5 days
RxNorm normalized name: fluvoxamine 100 MG
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anle138b (TEV-56286) as victim
Trial: NCT05072938
Drug: Axid Capsule 150mg
RxNorm normalized name: Axid
DrugBank: Nizatidine (DB00585)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nizatidine Monotherapy
Trial: NCT04776993
Drug: Methimazole
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole for 72 weeks
Trial: NCT06375824
Drug: Bufei Recipe
RxNorm normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bufei Recipe: Roasted Astragalus, Codonopsis pilosula, Walnut kernels, Sichuan Fritillaria, Angelica sinensis, Stir fried Purple Su Zi, Honey Baibu, Roasted Purple Aster, etc. Take 1 dose daily, 5 days a week.
Trial: NCT05533164
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1000mg rituximab in 250ml NaCl 0.9% intravenously
Trial: NCT04993391
Drug: JS111(AP-L1898 Capsules)
RxNorm normalized name: AP
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg, QD
Trial: NCT04993391
Drug: JS111(AP-L1898 Capsules)
RxNorm normalized name: AP
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg, QD
Trial: NCT04993391
Drug: JS111(AP-L1898 Capsules)
RxNorm normalized name: AP
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 160 mg, QD
Trial: NCT04993391
Drug: JS111(AP-L1898 Capsules)
RxNorm normalized name: AP
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 240 mg, QD
Trial: NCT04993391
Drug: JS111(AP-L1898 Capsules)
RxNorm normalized name: AP
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 320 mg, QD
Trial: NCT06125106
Drug: Blinatumomab
RxNorm normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Haploidentical hematopoietic stem cell transplantation was performed using a Conditioning regimen containing Blinatumomab. 28ug of Blinatumomab was administered intravenously once a day for a total of 7 days, followed by a routine conditioning regimen and haploid hematopoietic stem cell transplantation.
Trial: NCT04234867
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: once daily for 5 days
Trial: NCT05193188
Drug: Anlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib 12mg per person per day, continuous medication for 2 weeks and 1 week off, 3 weeks 1 cycle, until disease progression or intolerable toxicity
Trial: NCT05193188
Drug: PD-1 inhibitor
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection, once every 3 weeks, until the disease progression or intolerable toxicity
Trial: NCT05039606
Drug: Nedaplatin
RxNorm normalized name: Nedaplatin
DrugBank: Nedaplatin (DB13145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nedaplatin is a second-generation platinum-like derivative, which is a cell cycle non-specific drug, with a mechanism of action and efficacy similar to cisplatin, and a wide anti-cancer spectrum
Trial: NCT05039606
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin, aka cis-dichlorodiamineplatin, is a platinum-containing anticancer drug
Trial: NCT05924594
Drug: CTx-1301 - Dexmethylphenidate 6.25mg
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
Trial: NCT05924594
Drug: CTx-1301 - Dexmethylphenidate 12.5mg
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
Trial: NCT05924594
Drug: CTx-1301 - Dexmethylphenidate 18.75mg
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
Trial: NCT05924594
Drug: CTx-1301 - Dexmethylphenidate 25.0mg
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
Trial: NCT05924594
Drug: CTx-1301 - Dexmethylphenidate 31.25mg
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
Trial: NCT05924594
Drug: CTx-1301 - Dexmethylphenidate 37.5mg
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
Trial: NCT04884997
Drug: toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: toripalimab 3mg/kg, Q2w;
Trial: NCT04884997
Drug: Temozolomide Injection
RxNorm normalized name: temozolomide Injection
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide 150mg/m2,d1-5,Q4w
Trial: NCT05659368
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tirzepatide once weekly
Trial: NCT06393413
Drug: Donepezil Hydrochloride Tablets
RxNorm normalized name: Donepezil Hydrochloride Tablets
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil Hydrochloride Tablets
Trial: NCT00277550
Drug: Tegaserod and Placebo
DrugBank: Tegaserod (DB01079)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04415333
Drug: Sodium Butyrate 5 mmol
RxNorm normalized name: butyrate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enema-based delivery of 5 mmol butyrate in 0.9% saline, (60 mL total)
Trial: NCT04415333
Drug: Sodium Butyrate 80 mmol
RxNorm normalized name: butyrate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enema-based delivery of 80 mmol butyrate in 0.9% saline, (60 mL total)
Trial: NCT00000878
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00000878
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000878
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05100329
Drug: Mitoxantrone Hydrochloride Liposome injection
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg/m\^2, IV, on day 1 of every 3 weeks (q3w, a cycle)
Trial: NCT05623384
Drug: Mecobalamin Tablets
RxNorm normalized name: mecobalamin Oral Tablet
DrugBank: Mecobalamin (DB03614)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral Mecobalamin Tablets tid-8
Trial: NCT04668768
Drug: Glucarpidase
RxNorm normalized name: Glucarpidase
DrugBank: Glucarpidase (DB08898)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucarpidase injection to prevent toxicities due to high dose methotrexate treatment
Trial: NCT05298163
Drug: Calcitriol capsules
RxNorm normalized name: Calcitriol Capsules
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcitriol under the name of Oscal, 0.25 mcg/day (minimum dose) will be given for 6 months, starting at the day of the time when inclusion criteria have been met.
Trial: NCT00000634
Drug: Nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04806919
Drug: Progesteron TID
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: increasing the dose